Cas:923012-40-2 Fmoc-D-Cyclopropylglycine manufacturer & supplier

We serve Chemical Name:Fmoc-D-Cyclopropylglycine CAS:923012-40-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Fmoc-D-Cyclopropylglycine

Chemical Name:Fmoc-D-Cyclopropylglycine
CAS.NO:923012-40-2
Synonyms:(2R)-Cyclopropyl{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}acetic acid;REF DUPL: Fmoc-D-Cyclopropylglycine;(R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-cyclopropylacetic acid;Cyclopropaneacetic acid, α-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (αR)-
Molecular Formula:C20H19NO4
Molecular Weight:337.369
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:577.1±33.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.639
PSA:75.63000
Exact Mass:337.131409
LogP:3.91

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (2R)-Cyclopropyl{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclopropaneacetic acid, α-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (αR)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-cyclopropylacetic acid Use and application,Cyclopropaneacetic acid, α-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (αR)- technical grade,usp/ep/jp grade.


Related News: Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. Fmoc-D-Cyclopropylglycine manufacturer As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth. Fmoc-D-Cyclopropylglycine supplier Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. Fmoc-D-Cyclopropylglycine vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. Fmoc-D-Cyclopropylglycine factory As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth.